Aesplla 5ml

aesPLLA® 5 ml contains a dry powder totaling 365 mg, with 150 mg of active poly-L-lactic acid (PLLA). The remaining ingredients—sodium carboxymethylcellulose and mannitol—help stabilize and suspend the particles but are not bio-active.

This concentration places aesPLLA® in the category of collagen bio-stimulators rather than traditional fillers. The PLLA microparticles trigger fibroblast activity, encouraging the body’s own collagen to regenerate over time.

The quantity of PLLA determines the level and duration of collagen stimulation, but results also depend on factors such as injection depth, dilution, and patient metabolism. Injection into the deep dermis or sub-dermis allows the particles to act gradually and naturally.

Overall, aesPLLA®’s defined 150 mg PLLA concentration supports transparent dosing and predictable performance, forming the foundation of its long-lasting rejuvenation effect.

aesPLLA® is designed to correct facial volume loss and smooth wrinkles by promoting collagen formation. It is indicated for shallow to deep nasolabial folds, marionette lines, cheeks, temples, jawline, and similar facial zones. Some practitioners also extend use to the neck or hands.

The ideal patient is someone seeking a natural, progressive improvement in skin firmness and facial contour—typically individuals in their 30s or older with mild to moderate soft-tissue loss.

Unlike hyaluronic acid fillers, aesPLLA® does not provide an immediate plumping effect. Instead, results build gradually as collagen increases beneath the skin, creating a subtle and durable lift that can last up to 2–3 years.

Most treatment plans involve 2–3 sessions spaced 4–6 weeks apart, allowing optimal collagen stimulation and layering of results.

Each aesPLLA® 5 ml package contains 1 vial (365 mg total, including 150 mg PLLA). The formula is supplied as a lyophilized powder that must be reconstituted with sterile water before use.

Needles or cannulas are not included, as this is a professional-use medical device. Practitioners are responsible for preparing the product according to manufacturer guidelines—typically mixing with sterile water 30 minutes to 2 hours before injection.

The product carries CE-mark certification and is classified as a Class III medical device in the EU. It is intended for professional use only and should be stored at ambient temperature.

aesPLLA® delivers gradual and long-lasting results. Visible improvement usually begins around 4 weeks after treatment, with effects continuing to develop over several months as collagen formation increases. Under optimal conditions, results may last up to 2–3 years, depending on patient age, lifestyle, metabolism, and injection technique. Maintenance sessions every 12–24 months can help sustain results. The delayed but enduring improvement distinguishes aesPLLA® from short-term fillers—making it ideal for patients seeking a slow, natural rejuvenation process.

Q1: Is aesPLLA® approved in the EU?
Yes. aesPLLA® holds CE-mark certification and is classified as a Class III medical device in the European Union. Practitioners should ensure compliance with their national regulations before use.

Q2: Can aesPLLA® be used on the hands or neck?
While primarily indicated for facial wrinkles and folds, aesPLLA® is sometimes used in off-label areas such as the neck and hands. This should only be performed by trained professionals aware of the relevant anatomical and safety considerations.

Q3: How many sessions are needed?
Typically, 2–3 sessions spaced 4–6 weeks apart are recommended to achieve optimal collagen stimulation. Maintenance sessions may be advised once every 12–24 months.

aesPLLA® is developed by Oreon Life Science, a South Korean company established in 2000 and based in Seoul. Oreon specializes in anti-aging solutions, dermal fillers, and bio-stimulatory agents distributed across more than 70 countries.

Positioned as a next-generation collagen stimulator, aesPLLA® focuses on gradual, natural, and long-lasting rejuvenation. The product reflects Oreon’s emphasis on clinical quality, safety, and biocompatibility.

While aesPLLA® is CE-marked for Europe, no FDA approval for the U.S. market is currently listed. Professionals should confirm regulatory status in their country before use.